Neurgain
Chronic back pain (traumatic and neuropathic) affects over 26 million Americans, of which about 7 million have spinal stiffness (spasticity). Current therapeutic management is not working: drugs in use have poor efficacy, and cause undesirable side effects such as resistance, dependency/abuse and other disorders.
The estimated annual economic burden of back pain is over $150 billion. Our mission is to positively impact this “pain” by means of our patented innovation to provide a therapy that works, improves patient’s quality of life and reduces the overall burden.
Neurgain Technologies, Inc., is a Delaware Corporation founded to license, develop and commercialize the technologies arising from Dr. Martin Marsala’s regenerative medical research at the University of California-San Diego (UCSD). The innovation is distinguished by a unique combination of a novel delivery method and a specially designed device for practicing it, both of which are patented.
The delivery method has been validated in both rodent and swine models; and we have verified the satisfactory functionality of a proof-of-concept device prototype.
Special Guest:
Sai Kumar, Principal, DiligentCXO
